Cat. No：GM-81801AB
Product：Anti-CLDN18.2 hIgG1 Antibody(LM-102)
Cat. No：GM-81801AB
Product：Anti-CLDN18.2 hIgG1 Antibody(LM-102)
GM-81801AB-10 10 μg
GM-81801AB-100 100 μg
GM-81801AB-1000 1mg
Species Reactivity Human
Clone LM-102
Source/Isotype Monoclonal Human IgG1,κ
Application Flow Cytometry
Specificity Detects CLDN18.2
Gene CLDN18.2
Other Names /
Gene ID 51208(Human）
Background The claudin18.2 (CLDN18.2) protein, an isoform of claudin18, a member of the tight junction protein family, is a highly selective biomarker with limited expression in normal tissues and often abnormal expression during the occurrence and development of various primary malignant tumors, such as gastric cancer/gastroesophageal junction (GC/GEJ) cancer, breast cancer, colon cancer, liver cancer, head and neck cancer, bronchial cancer and non-small-cell lung cancer. CLDN18.2 participates in the proliferation, differentiation and migration of tumor cells. Recent studies have identified CLDN18.2 expression as a potential specific marker for the diagnosis and treatment of these tumors. With its specific expression pattern, CLDN18.2 has become a unique molecule for targeted therapy in different cancers, especially in GC; for example, agents such as zolbetuximab (claudiximab, IMAB362), a monoclonal antibody (mAb) against CLDN18.2, have been developed.
Storage Store at 2-8°C short term (1-2 weeks). Store at ≤ -20°C long term.Avoid repeated freeze-thaw.
Formulation Phosphate-buffered solution, pH 7.2.
Endotoxin < 1 EU/mg, determined by LAL gel clotting assay
Cat. No：GM-81801AB
Product：Anti-CLDN18.2 hIgG1 Antibody(LM-102)
GM-81801AB-10 10 μg
GM-81801AB-100 100 μg
GM-81801AB-1000 1mg
Species Reactivity Human
Clone LM-102
Source/Isotype Monoclonal Human IgG1,κ
Application Flow Cytometry
Specificity Detects CLDN18.2
Gene CLDN18.2
Other Names /
Gene ID 51208(Human）
Background The claudin18.2 (CLDN18.2) protein, an isoform of claudin18, a member of the tight junction protein family, is a highly selective biomarker with limited expression in normal tissues and often abnormal expression during the occurrence and development of various primary malignant tumors, such as gastric cancer/gastroesophageal junction (GC/GEJ) cancer, breast cancer, colon cancer, liver cancer, head and neck cancer, bronchial cancer and non-small-cell lung cancer. CLDN18.2 participates in the proliferation, differentiation and migration of tumor cells. Recent studies have identified CLDN18.2 expression as a potential specific marker for the diagnosis and treatment of these tumors. With its specific expression pattern, CLDN18.2 has become a unique molecule for targeted therapy in different cancers, especially in GC; for example, agents such as zolbetuximab (claudiximab, IMAB362), a monoclonal antibody (mAb) against CLDN18.2, have been developed.
Storage Store at 2-8°C short term (1-2 weeks). Store at ≤ -20°C long term.Avoid repeated freeze-thaw.
Formulation Phosphate-buffered solution, pH 7.2.
Endotoxin < 1 EU/mg, determined by LAL gel clotting assay
